Jun Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun Zhou has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Xiangsheng Zhang
Department of Anesthesiology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
9 shared publicationsYingdong Deng
Department of Anesthesiology The Third Affiliated Hospital of Southern Medical University Guangzhou China
9 shared publicationsSimin Tang
Department of Anesthesiology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
8 shared publicationsYu Cao
Department of Anesthesiology The Third Affiliated Hospital of Southern Medical University Guangzhou China
8 shared publicationsLu Li
Department of Anesthesiology The Third Affiliated Hospital of Southern Medical University Guangzhou China
7 shared publicationsZiqiang Lin
Department of Anesthesiology The Third Affiliated Hospital of Southern Medical University Guangzhou China
7 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (11)
Zinc‐Coordinated Naringenin‐Loaded Dendritic Mesoporous Silica Nanoparticles Inhibit Microglial Pyroptosis to Alleviate Neuropathic Pain and Promote Functional Recovery After Spinal Cord Injury
Aims: Neuropathic pain after spinal cord injury (SCI) severely impairs quality of life, and current therapeutic options remain limited. Naringenin possesses anti‐inflammatory and antioxidant activities, but its clinical application is restricted by poor water solubility and low bioavailability. This study aims to identify the molecular target of naringenin and develop a targeted nanodelivery strategy to inhibit microglial pyroptosis for treating neuropathic pain after SCI. Methods: Mmp13 was identified as a key regulator of microglial pyroptosis through bioinformatics analysis, and naringenin‐Mmp13 binding was validated by molecular docking, surface plasmon resonance, cellular thermal shift assay, siRNA knockdown, and site‐directed mutagenesis. A microglia‐targeted dendritic mesoporous silica nanodelivery system loaded with zinc‐coordinated naringenin (DMSNs@(Nar‐Mg1)/Zn) was constructed and characterized. Anti‐pyroptotic efficacy was evaluated in a mouse SCI model via behavioral tests, Western blotting, immunofluorescence, and transmission electron microscopy. Results: Naringenin directly binds to Mmp13 at the Ala165 site, suppressing pyroptosis. A single intravenous injection of DMSNs@(Nar‐Mg1)/Zn significantly inhibited microglial pyroptosis, alleviated neuropathic pain, and promoted motor functional recovery, with superior efficacy to free naringenin and non‐targeted formulations. The nanoplatform downregulated NLRP3, GSDMD‐N, cleaved caspase‐1, IL‐18, IL‐1β, and exhibited excellent biocompatibility. Conclusion: This study establishes Mmp13 as a targetable regulator of pyroptosis after SCI and provides a synergistic targeted nanotherapeutic strategy with translational potential for neuropathic pain treatment.
- 15 November 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (11)
Open AccessZinc‐Coordinated Naringenin‐Loaded Dendritic Mesoporous Silica Nanoparticles Inhibit Microglial Pyroptosis to Alleviate Neuropathic Pain and Promote Functional Recovery After Spinal Cord Injury
Aims: Neuropathic pain after spinal cord injury (SCI) severely impairs quality of life, and current therapeutic options remain limited. Naringenin possesses anti‐inflammatory and antioxidant activities, but its clinical application is restricted by poor water solubility and low bioavailability. This study aims to identify the molecular target of naringenin and develop a targeted nanodelivery strategy to inhibit microglial pyroptosis for treating neuropathic pain after SCI. Methods: Mmp13 was identified as a key regulator of microglial pyroptosis through bioinformatics analysis, and naringenin‐Mmp13 binding was validated by molecular docking, surface plasmon resonance, cellular thermal shift assay, siRNA knockdown, and site‐directed mutagenesis. A microglia‐targeted dendritic mesoporous silica nanodelivery system loaded with zinc‐coordinated naringenin (DMSNs@(Nar‐Mg1)/Zn) was constructed and characterized. Anti‐pyroptotic efficacy was evaluated in a mouse SCI model via behavioral tests, Western blotting, immunofluorescence, and transmission electron microscopy. Results: Naringenin directly binds to Mmp13 at the Ala165 site, suppressing pyroptosis. A single intravenous injection of DMSNs@(Nar‐Mg1)/Zn significantly inhibited microglial pyroptosis, alleviated neuropathic pain, and promoted motor functional recovery, with superior efficacy to free naringenin and non‐targeted formulations. The nanoplatform downregulated NLRP3, GSDMD‐N, cleaved caspase‐1, IL‐18, IL‐1β, and exhibited excellent biocompatibility. Conclusion: This study establishes Mmp13 as a targetable regulator of pyroptosis after SCI and provides a synergistic targeted nanotherapeutic strategy with translational potential for neuropathic pain treatment.
- Open Access
- 8 October 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1) , 556
Single-cell, spatial, and machine learning analyses identify ANKIB1 as an oligodendrocyte-anchored palmitoylation-associated candidate biomarker of Alzheimer’s disease
Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and cognitive decline, yet most candidate therapies targeting amyloid-β have failed to robustly modify disease progression, underscoring an incomplete mechanistic understanding. Oligodendrocytes (ODCs) have recently emerged as active contributors to AD pathology, but the cell-type-specific role of protein S-palmitoylation — a reversible lipid post-translational modification regulating membrane targeting and trafficking — in AD remains uncharacterized. Here we performed an integrated multi-omics analysis combining single-cell RNA sequencing (GSE233208; 48,714 cells), five bulk transcriptomic cohorts (769 samples), and 10× Visium spatial transcriptomic data from 16 brain sections. Palmitoylation activity was quantified at single-cell resolution using a curated 46-gene set; machine learning frameworks (LASSO, random forest, and XGBoost) were used to distil a parsimonious biomarker panel; and four complementary metrics (Jaccard index, overlap coefficient, colocalization percentage, and odds ratio) were applied to evaluate spatial gene–cell colocalization. Oligodendrocytes emerged as the cell population most strongly enriched for palmitoylation activity in the AD brain, supported by per-cell-type scoring, odds ratio enrichment, and an ODC-anchored 658-gene palmitoylation module. Intersection with AD-associated differentially expressed genes yielded 89 candidate genes, from which machine learning identified a seven-gene biomarker panel (ANKIB1, SPAG9, HBP1, SLC25A29, FAM171A1, ATXN10, and NDUFV1). ANKIB1 consistently topped every layer of analysis, with the highest AUC for AD discrimination (0.813, 95% CI 0.782–0.844) and persistent spatial colocalization with ODC-enriched regions across early AD and AD. Network pharmacology nominated AHR and TRIM11 as candidate upstream regulators and catalogued compounds with reported gene interactions. These findings identify the ODC–palmitoylation axis as a previously underappreciated dimension of AD biology and position ANKIB1 as a leading candidate biomarker of ODC dysfunction in AD.
- 8 October 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1) , 556
Open AccessSingle-cell, spatial, and machine learning analyses identify ANKIB1 as an oligodendrocyte-anchored palmitoylation-associated candidate biomarker of Alzheimer’s disease
Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and cognitive decline, yet most candidate therapies targeting amyloid-β have failed to robustly modify disease progression, underscoring an incomplete mechanistic understanding. Oligodendrocytes (ODCs) have recently emerged as active contributors to AD pathology, but the cell-type-specific role of protein S-palmitoylation — a reversible lipid post-translational modification regulating membrane targeting and trafficking — in AD remains uncharacterized. Here we performed an integrated multi-omics analysis combining single-cell RNA sequencing (GSE233208; 48,714 cells), five bulk transcriptomic cohorts (769 samples), and 10× Visium spatial transcriptomic data from 16 brain sections. Palmitoylation activity was quantified at single-cell resolution using a curated 46-gene set; machine learning frameworks (LASSO, random forest, and XGBoost) were used to distil a parsimonious biomarker panel; and four complementary metrics (Jaccard index, overlap coefficient, colocalization percentage, and odds ratio) were applied to evaluate spatial gene–cell colocalization. Oligodendrocytes emerged as the cell population most strongly enriched for palmitoylation activity in the AD brain, supported by per-cell-type scoring, odds ratio enrichment, and an ODC-anchored 658-gene palmitoylation module. Intersection with AD-associated differentially expressed genes yielded 89 candidate genes, from which machine learning identified a seven-gene biomarker panel (ANKIB1, SPAG9, HBP1, SLC25A29, FAM171A1, ATXN10, and NDUFV1). ANKIB1 consistently topped every layer of analysis, with the highest AUC for AD discrimination (0.813, 95% CI 0.782–0.844) and persistent spatial colocalization with ODC-enriched regions across early AD and AD. Network pharmacology nominated AHR and TRIM11 as candidate upstream regulators and catalogued compounds with reported gene interactions. These findings identify the ODC–palmitoylation axis as a previously underappreciated dimension of AD biology and position ANKIB1 as a leading candidate biomarker of ODC dysfunction in AD.
- Open Access
- 11 July 2026
- Published by Elsevier in Materials Today Bio
- Vol. 39
Targeted HA@Que-Mn Nanozymes Alleviate Postherpetic Neuralgia by Modulating Neuroinflammationa
- 11 July 2026
- Published by Elsevier in Materials Today Bio
- Vol. 39
Open AccessTargeted HA@Que-Mn Nanozymes Alleviate Postherpetic Neuralgia by Modulating Neuroinflammationa
- Open Access
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
Anesthesia-Induced Modulation of the NLRP3 Inflammasome–Gasdermin D Pyroptotic Axis in Perioperative Neurocognitive Disorders after Major Orthopedic Surgery: A Systematic Review, Multi-Omics Meta-Analysis, Trial Sequential Analysis, and Drug-Target Prioritization
.Background: Perioperative neurocognitive disorders (PND) affect 14–41% of elderly orthopedic patients and are linked to dementia risk. The NLRP3–GSDMD pyroptotic axis drives neuroinflammation, but whether anesthetic choice modulates this axis and whether dexmedetomidine adds benefit beyond propofol alone is unknown.Methods: We conducted a systematic review and meta-analysis of RCTs and cohorts comparing TIVA/propofol (±dexmedetomidine) versus volatile anesthesia in adult orthopedic surgery. Primary outcomes were postoperative IL-1β, IL-18, caspase-1, GSDMD-NT (SMD), and PND incidence (RR). Secondary analyses included transcriptomics, single-cell RNA-seq, eQTL–GWAS colocalization, molecular docking, and trial sequential analysis (TSA). GRADE assessed evidence certainty.Results: Thirty-five studies (n=4,892) were included. TIVA/propofol (±dexmedetomidine) reduced IL-1β (SMD -1.93), IL-18 (-1.99), caspase-1 (-1.89), and GSDMD-NT (-2.29; all p RIS=228). Volatile anesthesia upregulated NLRP3 (log2FC +1.31), GSDMD (+1.09), and IL1B (+1.57) (all FDR<0.001). Single-cell analysis localized expression to intermediate CD14+CD16+ monocytes. eQTL–GWAS colocalization was limited (H4=0.049) due to insufficient GWAS power. Dexmedetomidine bound NLRP3 (ΔG -8.2 kcal/mol) and GSDMD (ΔG -7.8 kcal/mol). Infection rates did not differ (RR 0.91).Conclusion: TIVA/propofol suppresses the NLRP3–GSDMD axis; dexmedetomidine provides additional GSDMD suppression. TIVA reduces PND in elderly patients (RR 0.36), with greatest benefit when dexmedetomidine is included. These findings support TIVA/dexmedetomidine for PND prevention and identify GSDMD as a tractable perioperative target.
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAnesthesia-Induced Modulation of the NLRP3 Inflammasome–Gasdermin D Pyroptotic Axis in Perioperative Neurocognitive Disorders after Major Orthopedic Surgery: A Systematic Review, Multi-Omics Meta-Analysis, Trial Sequential Analysis, and Drug-Target Prioritization
.Background: Perioperative neurocognitive disorders (PND) affect 14–41% of elderly orthopedic patients and are linked to dementia risk. The NLRP3–GSDMD pyroptotic axis drives neuroinflammation, but whether anesthetic choice modulates this axis and whether dexmedetomidine adds benefit beyond propofol alone is unknown.Methods: We conducted a systematic review and meta-analysis of RCTs and cohorts comparing TIVA/propofol (±dexmedetomidine) versus volatile anesthesia in adult orthopedic surgery. Primary outcomes were postoperative IL-1β, IL-18, caspase-1, GSDMD-NT (SMD), and PND incidence (RR). Secondary analyses included transcriptomics, single-cell RNA-seq, eQTL–GWAS colocalization, molecular docking, and trial sequential analysis (TSA). GRADE assessed evidence certainty.Results: Thirty-five studies (n=4,892) were included. TIVA/propofol (±dexmedetomidine) reduced IL-1β (SMD -1.93), IL-18 (-1.99), caspase-1 (-1.89), and GSDMD-NT (-2.29; all p RIS=228). Volatile anesthesia upregulated NLRP3 (log2FC +1.31), GSDMD (+1.09), and IL1B (+1.57) (all FDR<0.001). Single-cell analysis localized expression to intermediate CD14+CD16+ monocytes. eQTL–GWAS colocalization was limited (H4=0.049) due to insufficient GWAS power. Dexmedetomidine bound NLRP3 (ΔG -8.2 kcal/mol) and GSDMD (ΔG -7.8 kcal/mol). Infection rates did not differ (RR 0.91).Conclusion: TIVA/propofol suppresses the NLRP3–GSDMD axis; dexmedetomidine provides additional GSDMD suppression. TIVA reduces PND in elderly patients (RR 0.36), with greatest benefit when dexmedetomidine is included. These findings support TIVA/dexmedetomidine for PND prevention and identify GSDMD as a tractable perioperative target.
- Open Access
- 26 June 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Low-dose esketamine for postoperative fatigue after gynecological laparoscopic surgery: a randomized controlled trial
Background: Postoperative fatigue is a prevalent complication delaying early recovery after gynecological laparoscopic surgery, with no proven effective interventions. To investigate the effect of continuous intraoperative low-dose esketamine on postoperative fatigue in patients undergoing gynecological laparoscopic surgery. Methods: This single-center, double-blind, randomized placebo-controlled trial enrolled 116 elective gynecological laparoscopic surgery patients, randomly assigned 1:1 to the esketamine group (0.2 mg·kg⁻¹·h⁻¹ esketamine infusion during surgery, n = 58) or control group (equal volume normal saline, n = 58). The primary outcome was the incidence of postoperative fatigue on postoperative day 1 (POD1, Chalder Fatigue Scale score ≥ 4). Secondary outcomes included Chalder Fatigue Scale scores, 15-item Quality of Recovery (QoR-15) scores, Visual Analogue Scale (VAS) pain scores, perioperative drug consumption, and safety events. Results: In the primary intention-to-treat analysis, the incidence of POD1 postoperative fatigue was 23.3% (14/60) in the esketamine group and 40.0% (24/60) in the control group (risk difference − 16.7%, OR = 0.46, 95% CI 0.21–1.01, P = 0.050). Esketamine group had significantly lower POD1 fatigue scores, better recovery quality and pain control on POD1 and POD3, reduced intraoperative sufentanil and ephedrine consumption, (all P < 0.05). No significant differences in adverse events were observed between groups (all P > 0.05). Conclusion: Intraoperative low-dose esketamine shows a favorable effect on reducing postoperative fatigue, and significantly improves recovery quality and analgesia, without increasing adverse events in patients undergoing gynecological laparoscopic surgery. The primary ITT analysis shows a borderline significant reduction in fatigue incidence, which is supported by a statistically significant result in the per-protocol sensitivity analysis. Trial registration: This study was prospectively registered at the Chinese Clinical Trial Registry (ChiCTR, https://www.chictr.org.cn/showproj.html?proj=290957 ), with the clinical trial registration number ChiCTR2500112382, and the registration date is November 13, 2025.
- 26 June 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessLow-dose esketamine for postoperative fatigue after gynecological laparoscopic surgery: a randomized controlled trial
Background: Postoperative fatigue is a prevalent complication delaying early recovery after gynecological laparoscopic surgery, with no proven effective interventions. To investigate the effect of continuous intraoperative low-dose esketamine on postoperative fatigue in patients undergoing gynecological laparoscopic surgery. Methods: This single-center, double-blind, randomized placebo-controlled trial enrolled 116 elective gynecological laparoscopic surgery patients, randomly assigned 1:1 to the esketamine group (0.2 mg·kg⁻¹·h⁻¹ esketamine infusion during surgery, n = 58) or control group (equal volume normal saline, n = 58). The primary outcome was the incidence of postoperative fatigue on postoperative day 1 (POD1, Chalder Fatigue Scale score ≥ 4). Secondary outcomes included Chalder Fatigue Scale scores, 15-item Quality of Recovery (QoR-15) scores, Visual Analogue Scale (VAS) pain scores, perioperative drug consumption, and safety events. Results: In the primary intention-to-treat analysis, the incidence of POD1 postoperative fatigue was 23.3% (14/60) in the esketamine group and 40.0% (24/60) in the control group (risk difference − 16.7%, OR = 0.46, 95% CI 0.21–1.01, P = 0.050). Esketamine group had significantly lower POD1 fatigue scores, better recovery quality and pain control on POD1 and POD3, reduced intraoperative sufentanil and ephedrine consumption, (all P < 0.05). No significant differences in adverse events were observed between groups (all P > 0.05). Conclusion: Intraoperative low-dose esketamine shows a favorable effect on reducing postoperative fatigue, and significantly improves recovery quality and analgesia, without increasing adverse events in patients undergoing gynecological laparoscopic surgery. The primary ITT analysis shows a borderline significant reduction in fatigue incidence, which is supported by a statistically significant result in the per-protocol sensitivity analysis. Trial registration: This study was prospectively registered at the Chinese Clinical Trial Registry (ChiCTR, https://www.chictr.org.cn/showproj.html?proj=290957 ), with the clinical trial registration number ChiCTR2500112382, and the registration date is November 13, 2025.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-14
Single-Injection Liposomal Bupivacaine Adductor Canal Block for Pain Control and Recovery After Total Knee Arthroplasty: A Randomized Controlled Double‑Blinded Study
The efficacy of the adductor canal block (ACB) in multimodal analgesia following total knee arthroplasty (TKA) remains controversial. This study investigates the effects of local anesthetics single-injection ACB with different analgesic durations on TKA patients. This randomized controlled double‑blinded trial enrolled 90 patients undergoing primary TKA. Participants were randomized to receive ACB with either liposomal bupivacaine (LB), ropivacaine (15 mL of 0.3%), or in the control group, with 30 patients in each group. The primary end points included the static and dynamic visual analog scale (VAS) scores at 24 hours postoperatively. The secondary end points examined the static and dynamic pain scores at 6,12,48, and 72 hours postoperatively; the knee range of motion (ROM); quadriceps muscle strength; duration to first ambulation; opioid consumption; and related adverse events. Patients administered a LB single-injection ACB (LB-ACB) demonstrated significantly reduced VAS scores at static and dynamic phases at 24 hours, relative to the ropivacaine single-injection ACB (R-ACB) and control group patients. We recorded a median interquartile range [IQR] of 1 (0.0–2.0 [0–4]) vs. 3 (2.0–4.0 [0–5]) vs. 3 (2.0–4.0 [0–6]) for static pain scores and 2.5 (1.0–3.25 [0–5]) vs. 4 (4.0–5.0 [2–7]) vs. 5 (4.0–6.0 [3–7]) for dynamic pain scores (P<0.001). Both LB-ACB and R-ACB groups showed lower pain scores at 6 and 12 hours postoperatively versus control (P<0.05). Time to first rescue analgesia was prolonged in the LB group, and LB-ACB also improved early quadriceps strength and knee ROM. No significant adverse events or motor blockade occurred. Among patients undergoing TKA, LB single-injection ACB offers a significant analgesic advantage compared to ropivacaine, lasting up to 24 hours. After 48 hours, there is no difference in analgesic effects when compared to the control group.
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-14
Open AccessSingle-Injection Liposomal Bupivacaine Adductor Canal Block for Pain Control and Recovery After Total Knee Arthroplasty: A Randomized Controlled Double‑Blinded Study
The efficacy of the adductor canal block (ACB) in multimodal analgesia following total knee arthroplasty (TKA) remains controversial. This study investigates the effects of local anesthetics single-injection ACB with different analgesic durations on TKA patients. This randomized controlled double‑blinded trial enrolled 90 patients undergoing primary TKA. Participants were randomized to receive ACB with either liposomal bupivacaine (LB), ropivacaine (15 mL of 0.3%), or in the control group, with 30 patients in each group. The primary end points included the static and dynamic visual analog scale (VAS) scores at 24 hours postoperatively. The secondary end points examined the static and dynamic pain scores at 6,12,48, and 72 hours postoperatively; the knee range of motion (ROM); quadriceps muscle strength; duration to first ambulation; opioid consumption; and related adverse events. Patients administered a LB single-injection ACB (LB-ACB) demonstrated significantly reduced VAS scores at static and dynamic phases at 24 hours, relative to the ropivacaine single-injection ACB (R-ACB) and control group patients. We recorded a median interquartile range [IQR] of 1 (0.0–2.0 [0–4]) vs. 3 (2.0–4.0 [0–5]) vs. 3 (2.0–4.0 [0–6]) for static pain scores and 2.5 (1.0–3.25 [0–5]) vs. 4 (4.0–5.0 [2–7]) vs. 5 (4.0–6.0 [3–7]) for dynamic pain scores (P<0.001). Both LB-ACB and R-ACB groups showed lower pain scores at 6 and 12 hours postoperatively versus control (P<0.05). Time to first rescue analgesia was prolonged in the LB group, and LB-ACB also improved early quadriceps strength and knee ROM. No significant adverse events or motor blockade occurred. Among patients undergoing TKA, LB single-injection ACB offers a significant analgesic advantage compared to ropivacaine, lasting up to 24 hours. After 48 hours, there is no difference in analgesic effects when compared to the control group.
- 12 February 2026
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 110, 112145
Response to: No simple answer: Choosing regional analgesia for hip fracture pain
- 12 February 2026
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 110, 112145
Response to: No simple answer: Choosing regional analgesia for hip fracture pain
- Open Access
- 1 December 2025
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 109, 112082
Comparison of pericapsular nerve group block and supra-inguinal fascia iliaca compartment block for preoperative analgesia in elderly patients with hip fracture: A prospective, randomized controlled study
- 1 December 2025
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 109, 112082
Open AccessComparison of pericapsular nerve group block and supra-inguinal fascia iliaca compartment block for preoperative analgesia in elderly patients with hip fracture: A prospective, randomized controlled study
- 13 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178355
NF-κB/TOM6/PINK1-mediated mitophagy attenuates vascular calcification: Luteolin as a therapeutic modulator
- 13 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178355
NF-κB/TOM6/PINK1-mediated mitophagy attenuates vascular calcification: Luteolin as a therapeutic modulator
- Open Access
- 15 October 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (1) , 1-19
Exploring the role of cytochrome P450 family 1 subfamily B member 1 and quercetin in modulating neuropathic pain after spinal cord injury
Spinal cord injury (SCI) represents a notable global health challenge, with neuropathic pain (NP) being a common complication that intensifies patient suffering. Existing research tends to overlook the temporal aspects of NP and fails to offer targeted treatment options. To tackle this issue, the present study initially examined genome‑wide association study summaries related to NP, incorporating expression quantitative trait locus (eQTL) from blood samples through summary‑based Mendelian randomization. This allowed the investigation of the association between NP and eQTL, facilitating the identification of genes linked to the risk of NP. Following this, weighted gene co‑expression network analysis of a Gene Expression Omnibus dataset was utilized to identify SCI‑related module genes, resulting in the detection of 218 shared genes across these analyses. Subsequent functional enrichment assessments, protein‑protein interaction evaluations and machine learning technique analyses, including least absolute shrinkage and selection operator regression, random forest and support vector machine recursive feature elimination analyses, highlighted three central genes: Glycerol‑3‑phosphate dehydrogenase 1‑like, epoxide hydrolase 2 and cytochrome P450 family 1 subfamily B member 1 (CYP1B1). Additionally, network pharmacology and molecular docking analyses confirmed CYP1B1 as a viable therapeutic target. A analysis of single‑cell RNA sequencing datasets demonstrated an increase in CYP1B1 expression within spinal cord fibroblasts following SCI. Furthermore, quercetin (Que) was shown to inhibit CYP1B1 expression and reduce NP (based on mechanical paw withdrawal threshold and thermal paw withdrawal latency) in murine models. The results of the present study highlight the important role of spinal cord fibroblast CYP1B1 as a notable contributor to NP following SCI and suggest that Que may serve as a promising mechanism‑based therapeutic option.
- 15 October 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (1) , 1-19
Open AccessExploring the role of cytochrome P450 family 1 subfamily B member 1 and quercetin in modulating neuropathic pain after spinal cord injury
Spinal cord injury (SCI) represents a notable global health challenge, with neuropathic pain (NP) being a common complication that intensifies patient suffering. Existing research tends to overlook the temporal aspects of NP and fails to offer targeted treatment options. To tackle this issue, the present study initially examined genome‑wide association study summaries related to NP, incorporating expression quantitative trait locus (eQTL) from blood samples through summary‑based Mendelian randomization. This allowed the investigation of the association between NP and eQTL, facilitating the identification of genes linked to the risk of NP. Following this, weighted gene co‑expression network analysis of a Gene Expression Omnibus dataset was utilized to identify SCI‑related module genes, resulting in the detection of 218 shared genes across these analyses. Subsequent functional enrichment assessments, protein‑protein interaction evaluations and machine learning technique analyses, including least absolute shrinkage and selection operator regression, random forest and support vector machine recursive feature elimination analyses, highlighted three central genes: Glycerol‑3‑phosphate dehydrogenase 1‑like, epoxide hydrolase 2 and cytochrome P450 family 1 subfamily B member 1 (CYP1B1). Additionally, network pharmacology and molecular docking analyses confirmed CYP1B1 as a viable therapeutic target. A analysis of single‑cell RNA sequencing datasets demonstrated an increase in CYP1B1 expression within spinal cord fibroblasts following SCI. Furthermore, quercetin (Que) was shown to inhibit CYP1B1 expression and reduce NP (based on mechanical paw withdrawal threshold and thermal paw withdrawal latency) in murine models. The results of the present study highlight the important role of spinal cord fibroblast CYP1B1 as a notable contributor to NP following SCI and suggest that Que may serve as a promising mechanism‑based therapeutic option.